Liquidia Reports Q2 2025 Net Loss of $41.6M, EPS of $0.49; Product Revenue Reaches $6.5M Following YUTREPIA FDA Approval
I'm PortAI, I can summarize articles.
Liquidia Corporation reported a Q2 2025 net loss of $41.6 million, up from a $28.7 million loss in Q2 2024. Product revenue reached $6.5 million following FDA approval of YUTREPIA on May 23, 2025. R&D expenses decreased to $6.0 million, while SG&A expenses nearly doubled to $38.8 million. Total other expenses rose to $4.1 million. Cash and cash equivalents were $173.4 million as of June 30, 2025, down from $176.5 million at the end of 2024.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments